Treatment of Psoriatic Arthritis with Clinically Relevant Axial Disease

This protocol applies to patients with psoriatic arthritis in whom axial involvement is clinically relevant — a presentation managed distinctly from peripheral-dominant disease, with its own therapeutic priorities and response benchmarks.

The primary objective is relief of axial symptoms. Response is assessed at 4 weeks: persistent disease at that point is considered an insufficient response to first-line treatment.

Non-steroidal anti-inflammatory therapy is the cornerstone of first-line management in this setting. The full protocol — including the conditions under which continuous use is appropriate and how individual response guides ongoing decisions — is available in the complete structured regimen.